Literature DB >> 15728937

Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Manuel Cuenca-Estrella1, Alicia Gomez-Lopez, Guillermo Garcia-Effron, Laura Alcazar-Fuoli, Emilia Mellado, Maria J Buitrago, Juan L Rodriguez-Tudela.   

Abstract

Interactions in vitro between amphotericin B, itraconazole, voriconazole, and caspofungin against itraconazole-resistant Aspergillus fumigatus clinical strains were determined. Differential results were obtained depending on the criteria (MIC or minimal effective concentration) used. Caspofungin and voriconazole exhibited the most potent interactions, with synergy against at least 50% of isolates, and the average fractional concentration index was 0.38. Antagonism was not found for any combination.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728937      PMCID： PMC549263          DOI： 10.1128/AAC.49.3.1232-1235.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans.

Authors:  Michael A Rubin; Karen C Carroll; Barbara C Cahill
Journal:  Clin Infect Dis       Date:  2002-04-15       Impact factor: 9.079

2.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; F Persat; M F Monier; M A Piens; Ebga Network
Journal:  J Med Microbiol       Date:  1999-12       Impact factor: 2.472

4.  In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors:  Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

8.  In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole.

Authors:  E Chryssanthou
Journal:  Scand J Infect Dis       Date:  1997

9.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate.

Authors:  John W Slaven; Michael J Anderson; Dominique Sanglard; Graham K Dixon; Jacques Bille; Ian S Roberts; David W Denning
Journal:  Fungal Genet Biol       Date:  2002-08       Impact factor: 3.495
View more
  24 in total

1.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 5.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

6.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

7.  Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yasemin Oz
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

8.  Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.

Authors:  Joseph Meletiadis; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

9.  Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Authors:  Susanne Perkhofer; Daniel Jost; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

10.  Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

Authors:  V Nagappan; D Boikov; J A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.